<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1568">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04324866</url>
  </required_header>
  <id_info>
    <org_study_id>Gisondi 4</org_study_id>
    <nct_id>NCT04324866</nct_id>
  </id_info>
  <brief_title>Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy</brief_title>
  <official_title>Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universita di Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera Universitaria Integrata Verona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universita di Verona</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the prevalence and incidence of COVID-19 infection in patients with&#xD;
      chronic plaque psoriasis on immunosuppressant therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ongoing COVID-19 pandemic has hit Northern Italy (including the Veneto region)&#xD;
      particularly hard, causing several deaths and putting a huge strain on the Italian National&#xD;
      Healthcare System. In the absence of specific treatments, preventing the infection from&#xD;
      spreading remains the only effective measure. There is a lot of apprehension both from&#xD;
      doctors (including dermatologists, rheumatologists and gastroenterologists) and their&#xD;
      patients that immunosuppressive medications (biologics, methotrexate, ciclosporin and&#xD;
      corticosteroids) might lead to an increased susceptibility to COVID-19 infection or&#xD;
      negatively influence the course of the infection. However, there is currently a lack of&#xD;
      scientific evidence to recommend whether immunosuppressive treatments should or should not be&#xD;
      continued in patients who have no symptoms of COVID-19 infection. Besides, treatment&#xD;
      discontinuation would cause flare-ups of diseases - such as plaque psoriasis, psoriatic&#xD;
      arthritis and inflammatory bowel diseases - which are invalidating and have a relatively high&#xD;
      prevalence in the Veneto population. In the Unit of Dermatology of the Azienda Ospedaliera&#xD;
      Universitaria Intergrata di Verona alone, more than 2000 patients are currently being treated&#xD;
      with immunosuppressive agents. As of now, there are no data available on the prevalence and&#xD;
      incidence of COVID-19 infection in patients with immune-mediated diseases, nor can data from&#xD;
      randomized clinical trials be extrapolated to the susceptibility to COVID-19 infection in&#xD;
      patients on biologic drugs. This study aims to assess the prevalence and incidence of&#xD;
      COVID-19 infection in patients with chronic plaque psoriasis on immunosuppressive therapy and&#xD;
      to identify associated risk factors. Such data would prove invaluable for clinicians dealing&#xD;
      with patients on immunosuppressive agents during the coronavirus outbreak.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Point prevalence of COVID-19 infection</measure>
    <time_frame>Baseline up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of COVID-19 infection</measure>
    <time_frame>Baseline up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects presenting fever or respiratory symptoms</measure>
    <time_frame>Baseline up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the relationship between COVID-19 infection and chronic pharmacological treatments</measure>
    <time_frame>Baseline up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the relationship between COVID-19 infection and comorbid medical conditions</measure>
    <time_frame>Baseline up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Patients with chronic plaque psoriasis on immunosuppressant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Psoriatic patients' partners</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Patients with atopic dermatitis treated with dupilumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Nasopharyngeal swab</intervention_name>
    <description>Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasopharyngeal swabs&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enroll patients from the Unit of Dermatology of Azienda Ospedaliera&#xD;
        Universitaria di Verona and their partners.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Group 1&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 to 75 years old&#xD;
&#xD;
          -  Individuals with a clinical diagnosis of moderate-to-severe chronic plaque psoriasis&#xD;
             confirmed by the Investigator&#xD;
&#xD;
          -  Continuous immunosuppressive therapy (etanercept, adalimumab, infliximab, ustekinumab,&#xD;
             secukinumab, ixekizumab, brodalumab, guselkumab, apremilast, methotrexate,&#xD;
             ciclsoporin, acitretin) for the past 3 months&#xD;
&#xD;
          -  Is willing and able to sign informed consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unwilling to undergo noasopharyngeal swab&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
        Group 2&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 to 75 years old&#xD;
&#xD;
          -  Partner of a patient with psoriasis enrolled in the study&#xD;
&#xD;
          -  Is willing and able to sign informed consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Personal history of psoriasis&#xD;
&#xD;
          -  Ongoing immunosuppressive therapy&#xD;
&#xD;
          -  Patients unwilling to undergo noasopharyngeal swab&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
        Group 3&#xD;
&#xD;
          -  Aged 18 to 75 years old&#xD;
&#xD;
          -  Individuals with a clinical diagnosis of moderate-to-severe atopic dermatitis&#xD;
             confirmed by the Investigator&#xD;
&#xD;
          -  Continuous therapy with dupilumab for the past 3 months&#xD;
&#xD;
          -  Is willing and able to sign informed consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unwilling to undergo noasopharyngeal swab&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paolo Gisondi</last_name>
    <phone>+39 0458122547</phone>
    <email>paolo.gisondi@univr.it</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universita di Verona</investigator_affiliation>
    <investigator_full_name>Paolo Gisondi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>immunosuppressant therapy</keyword>
  <keyword>covid 19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

